Interim report

January 1 – June 30, 2015
The second quarter in figures

  · Total net sales amounted to TSEK 918 (258).
  · The loss after tax amounted to TSEK 10,939 (11,552).
  · The loss per share amounted to SEK 1.80 (2.32).
  · The cash flow from current operations was negative in the amount of
TSEK 13,858 (7,959).

The half-year in figures

  · Total net sales amounted to TSEK 1,975 (322).
  · The loss after tax amounted to TSEK 20,118 (20,564).
  · The loss per share amounted to SEK 3.63 (4.13).
  · The cash flow from current operations was negative in the amount of
TSEK 23,055(18,209).

Important events during the quarter

  · In April, SciBase announced its intention to launch an Initial Public
Offering and listing on Nasdaq First North.
  · At an Extraordinary General Meeting on April 28, resolutions were taken to:

-      introduce a share-based incentive program,

-      consolidate shares and reduce the share capital,

-      authorize the Board to make decisions regarding new share issues

  · The Company completed a rights issue that raised MSEK 165 before issue
costs. The Offering was significantly oversubscribed, resulting in a
substantially broadened shareholder base consisting of both institutions and
private shareholders. .
  · The Company’s shares were listed on Nasdaq First North on June 2nd.
  · Vinnova granted MSEK 3.9 for the development of the next generation device
to SciBase and KTH.
  · In April, an exclusive distributor agreement for the Austrian market was
signed with Intramed Handels GesmbH.
  · The Company expanded its sales resources in Germany.
  · In April, SciBase established a Scientific Advisory Board consisting of
international experts in the field of skin cancer
  · The Company received an additional US patent approval.

Important events after the end of the period

  · The Company announced that Pareto Securities has exercised the possibility
to, in connection with the initial public offering of SciBase Holding AB (publ)
(“SciBase”), carry out stabilization-like transactions.

Financial overview

                                                               July 1
                                                               2014 -
                               Apr 1           Jan 1           Jun 30   Jan 1 -
                               - Jun           - Jun           2015     Dec 31
                               30              30
THE GROUP                      2015    2014    2015    2014    Rolling  2014
                                                               -12
Net sales, SEK ths             918     258     1 975   322     3 253    1 600
Gross margin, %                -34,5%  -10,1%  -14,6%  -11,2%  -25,5%   -36,0%

Equity/Asset ratio, %          91,4%   84,8%   91,4%   84,8%   91,4%    78,5%
Net indebtness, multiple       0,09    0,18    0,09    0,18    0,09     0,27
Cash equivalents, SEK ths      165     46      165     46      165 595  27 566
                               595     903     595     903
Cashflow from operating        -13     -7      -23     -18     -41 923  -37 077
activities, SEK ths            858     959     055     209
Earnings per share (before     -1,80   -2,32   -3,63   -4,13   -7,26    -7,78
and after dilution), SEK*
Shaeholder's equity per        27,41   10,20   30,13   10,20   31,71    6,55
share, SEK*
Average number of shares,      6 085   4 985   5 535   4 983   5 260    4 984
000'*
Number of shares at closing    8 285   4 985   8 285   4 985   8 285    4 985
of period, 000'*
Average number of employees    13      11      14      11      13       12
*Adjusted for in May 2015
performed reversed split,
40:1
For further information please contact:

Simon Grant, CEO, tele :   46 72 887 43 99

Michael Colérus, CFO, tele : 46 70 341 34 72
About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm
that has developed a unique point-of-care device for the accurate detection of
malignant melanoma. Its product, Nevisense, helps doctors to detect malignant
melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig
Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden.
Nevisense is based on substantial research and has achieved excellent results in
the largest clinical study ever conducted on the detection of malignant
melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and
is awaiting FDA clearance in the United States. Nevisense is based on a method
called Electrical Impedance Spectroscopy (EIS), which uses the varying
electrical properties of human tissue to categorize cellular structures and
thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB").
Avanza is Certified Adviser. Further information is available on
www.scibase.com.